1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,534 | 2,608 | 11:44 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| Mo | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT INITIAL CLINICAL READOUT OF GFH276 (AN ORAL MOLECULAR-GLUE PAN RAS INHIBITOR) PRESENTED AS LATE-BREAKING ABSTRACT ... | 2 | HKEx | ||
| 15.10. | GENFLEET-B: Oral KRAS G12D Inhibitor Achieves Positive Progress in Multiple Domestic and Overseas Clinical Studies | 1 | AASTOCKS | ||
| GENFLEET THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.10. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375/VS-7375 (ORAL KRAS G12D INHIBITOR) ACHIEVES POSITIVE PROGRESS ACROSS MULTIPLE CLINICAL STUDIES IN CHINA ... | 1 | HKEx | ||
| 09.10. | GENFLEET-B Repurchases 135,000 Shares on Thu for HKD3.83 million | 1 | AASTOCKS | ||
| 08.10. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 28.09. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 24.09. | GENFLEET-B (02595): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 24.09. | GENFLEET-B (02595): RESIGNATION OF NON-EXECUTIVE DIRECTOR | 5 | HKEx | ||
| 23.09. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT DISCLOSURE ARRANGEMENTS FOR CLINICAL DATA FROM STUDIES OF GFH375 AND GFH276 | 1 | HKEx | ||
| 22.09. | GENFLEET-B (02595): ANNOUNCEMENT PURSUANT TO RULE 13.10 OF THE LISTING RULES | 2 | HKEx | ||
| 21.09. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT ON THE PROGRESS OF SHARE REPURCHASE | 1 | HKEx | ||
| 17.09. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 16.09. | GENFLEET-B (02595): 2026 INTERIM REPORT | 1 | HKEx | ||
| 15.09. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FAVORABLE PHASE II EFFICACY DATA OF GFH375 (ORAL KRAS G12D INHIBITOR) MONOTHERAPY IN PRETREATED NSCLC PRESENTED ... | 1 | HKEx | ||
| 09.09. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 02.09. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 26.08. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375, ORAL KRAS G12D INHIBITOR, ADVANCES INTO A PHASE II STUDY EVALUATING MONOTHERAPY AND COMBINATION REGIMENS ... | 1 | HKEx | ||
| 21.08. | GENFLEET-B (02595): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 20.08. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 ADVANCES INTO A NOVEL PHASE II STUDY FEATURING TWO FIRST-IN-WORLD COMBINATION THERAPIES FOR PANCREATIC ... | 2 | HKEx |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 288,62 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DISC MEDICINE | 82,84 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,200 | 0,00 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,235 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 97,48 | -0,08 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| KYMERA THERAPEUTICS | 122,55 | 0,00 % | Oppenheimer raises Kymera Therapeutics price target on drug data | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 12,585 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial | Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,510 | 0,00 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| RAPPORT THERAPEUTICS | 24,190 | 0,00 % | Rapport Therapeutics bricht ein: Großvolumige Kapitalerhöhung mit hohem Abschlag belastet Kurs | ||
| 4D MOLECULAR THERAPEUTICS | 12,780 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME | 4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 31,980 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints Rob Scott, MD to Board of Directors | ||
| COGENT BIOSCIENCES | 31,980 | 0,00 % | Stifel bekräftigt Kaufempfehlung für Cogent Biosciences nach ESMO-Daten | ||
| PRIME MEDICINE | 5,225 | -0,29 % | Prime Medicine, Inc.: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation... ► Artikel lesen | |
| ABSCI | 12,100 | 0,00 % | Jefferies nimmt Absci mit "Buy" auf - Potenzial bei Wirkstoff gegen Haarausfall im Fokus |
GENFLEET THERAPEUTICS SHANGHAI INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,531 Euro und damit -9,27 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLEET THERAPEUTICS SHANGHAI INC finden Sie auf Wallstreet Online.